Prior studies do not address racial and ethnic disparities in essential new drug use and whether disparities decrease through time. Using the Medical Expenditure Panel Survey (1996-2001), racial and ethnic disparities were examined separately by comparing non-Hispanic whites to non-Hispanic blacks and Hispanic whites, respectively. New drugs were defined as approved within the past 5 years, and an expert panel identified essential drugs. Negative binomial models adjusted for socioeconomic and health characteristics. The mean annual number of times essential new drugs were obtained among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites were 1.02, 0.94, and 0.70, respectively. After adjusting for confounders, ethnic disparities generally were not significant, but racial disparities became significant. This study did not identify declining disparities during early years of drugs’ life cycles. Disparities exist in new, essential drug acquisition between non-Hispanic whites and non-Hispanic blacks. Socioeconomic and health characteristics explain many of the observed disparities.
Agency for Healthcare Research and Quality. 2003. Data & publications. Retrieved May 5, 2004, from http://www.meps.ahrq.gov/data_public.htm.
2.
Andersen, R. M., and P. Davidson. 2001. Improving access to care in America: Individual and contextual indicators. In Changing the U.S. health care system, edited by R. M. Andersen, T. H. Rice, and G. F. Kominski, 13-40. San Francisco: Jossey-Bass.
3.
Baum, C. F., and N. J. Cox. 2002. WHITETST: Stata module to perform White’s test for heteroskedasticity. Retrieved May 3, 2004, from http://ideas.repec.org/c/boc/bocode/s390601.html.
4.
Blazer, D. G., G. F. Hybels, E. M. Simonsick, and F. T. Hanlon. 2000. Marked differences in antidepressant use by race in an elderly community sample: 1986-1996. American Journal of Psychiatry157: 1089-1094.
5.
Centers for Disease Control and Prevention. 2005a. Eliminating racial & ethnic health disparities. Retrieved May 7, 2005, from http://www.cdc.gov/omh/AboutUs/Disparities.htm.
6.
Centers for Disease Control and Prevention. 2005b. Life expectancy hits record high. Retrieved February 28, 2005, from http://www.cdc.gov/od/oc/media/pressrel/fs050228.htm.
7.
Cerner Multum, Inc.2006. Lexicon. Retrieved March 6, 2006, from http://www.multum.com/Lexicon.htm.
8.
Chen, A. Y., and R-K. Y. Chang. 2002. Factors associated with prescription drug expenditures among children: An analysis of the Medical Expenditure Panel Survey. Pediatrics109: 728-732.
9.
Collins, K. S., A. Hall, and C. Neuhaus. 1999. U.S. minority health: A chartbook. New York: The Commonwealth Fund.
10.
Daumit, G. L., R. M. Crum, E. Guallar, N. R. Powe, A. B. Primm, D. M. Steinwachs, and D. E. Ford. 2003. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Archives of General Psychiatry60(2): 121-128.
11.
Elkind, M. S., R. Sciacc, B. Boden-Albala, T. Rundek, M. C. Paik, and R. L. Sacco. 2003. Moderate alcohol consumption reduces risk of ischemic stroke: The Northern Manhattan Study. Stroke37(1): 13-19.
12.
Greene, W. H.2000. Econometric analysis. 4th ed.Upper Saddle River, NJ: Prentice Hall.
13.
Guagliardo, M. F., S. J. Teach, Z. J. Huang, J. M. Chamberlain, and J. G. Joseph. 2003. Racial and ethnic disparities in pediatric appendicitis rupture rate. Academic Emergency Medicine10: 1218-1227.
14.
Hahn, B. A.1995. Children’s health: Racial and ethnic differences in the use of prescription medications. Pediatrics95: 727-732.
15.
Hanlon, J. T., G. G. Fillenbaum, B. Burchett, W. E. Wall Jr., C. Service, D. G. Blazer, and L. K. George. 1992. Drug-use patterns among black and nonblack community-dwelling elderly. Annals of Pharmacotherapy26: 679-685.
16.
Harris, B. L., A. S. Stergachis, and L. D. Ried. 1990. The effect of drug-copayments on utilization and cost of pharmaceuticals in a health maintenance organization. Medical Care28: 907-917.
17.
Jablonski, K. A., and M. F. Guagliardo. 2005. Pediatric appendicitis rupture rate: A national indicator of disparities in healthcare access. Population Health Metrics3: 4-4.
18.
Jones, C. P.2000. Levels of racism: A theoretical framework and a gardener’s tale. American Journal of Public Health90: 1212-1215.
19.
Jones, C. P.2001. Invited commentary: “Race,” racism, and the practice of epidemiology. American Journal of Epidemiology154(4): 299-304.
20.
Khandker, R. K., and L. J. Simoni-Wastila. 1998. Differences in prescription drug utilization and expenditures between blacks and whites in the Georgia Medicaid population. Inquiry35: 78-87.
21.
Kleinbaum, D. G., L. L. Kupper, and H. Morgenstern. 1982. Epidemiologic research principles and quantitative methods. Belmont, CA: Lifetime Learning Publications.
22.
Krieger, N.2000. Refiguring “race”: Epidemiology, racialized biology, and biological expressions of race relations. International Journal of Health Services30(1): 211-216.
23.
Lahr, M. B., K. D. Rosenberg, and J. A. Lapidus. 2005. Bedsharing and maternal smoking in a population-based survey of new mothers. Pediatrics116(4): e530-e542.
24.
LaVeist, T. A., K. J. Nickerson, and J. V. Bowie. 2000. Attitudes about racism, medical mistrust, and satisfaction with care among African American and white cardiac patients. Medical Care Research and Review57(supp. 1): 146-161.
25.
Laws, M. B.2001. Race and ethnicity in biomedical and health services research. Archives of Pediatrics & Adolescent Medicine155(8): 972-973.
26.
Liang, K. Y., and S. L. Zeger. 1986. Longitudinal data analysis using generalized linear models. Biometrika73: 13-22.
27.
Lichtenberg, F. R.2001. Are the benefits and newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs20(5): 241-251.
28.
Mayberry, R. M., F. Mili, and E. Ofili. 2000. Racial and ethnic differences in access to medical care. Medical Care Research and Review57(supp. 1): 108-145.
29.
Messer, L. C., J. S. Kaufman, N. Dole, D. A. Savitz, and B. A. Laraia. 2005. Neighborhood crime, deprivation, and preterm birth. Annals of Epidemiology. (Published ahead of print November 14, 2005.)
30.
Moore, R. D., D. Stanton, R. Gopalan, and R. E. Chaisson. 1994. Racial differences in the use of drug therapy for HIV disease in an urban community. New England Journal of Medicine330: 763-768.
31.
Mullins, C. D., J. Wang, F. B. Palumbo, and B. Stuart. 2001. The impact of pipeline drugs on drug spending growth. Health Affairs20: 210-215.
32.
Palacio, H., J. G. Kahn, T. A. Richards, and S. F. Morin. 2002. Effect of race and/or ethnicity in use of antiretroviral and prophylaxis for opportunistic infection: A review of the literature. Public Health Reports117: 233-251.
33.
Pancholi, M., and M. Stagnitti. 2004. Outpatient prescribed medicines: A comparison of use and expenditures, 1987 and 2001. Statistical Brief #33. Rockville, MD: Agency for Healthcare Research and Quality. Retreived January 23, 2005, from http://www.meps.ahrq.gov/papers/st33/stat33.htm.
34.
Phillips, V. L., and A. Atherly. 2002. Prescription drug costs for dually eligible people in a Medicaid home- and community-based services program. Journal of the American Geriatrics Society50(7): 1283-1288.
35.
Schneider, E. C., A. M. Zaslavsky, and A. M. Epstein. 2002. Racial disparity in the quality of care for enrollees in Medicare managed care. The Journal of the American Medical Association287: 1288-1294.
36.
Sirey, J. A., B. S. Meyers, M. L. Bruce, G. S. Alexopoulos, D. A. Perlick, and P. Raue. 1999. Predictors of antidepressant prescription and early use among depressed outpatients. American Journal of Psychiatry156: 690-696.
37.
Smedley, B. D., A. Y. Stith, and A. R. Nelson, eds. 2002. Unequal treatment: Confronting racial and ethnic disparities in health care. Landover, MD: Institute of Medicine.
38.
Smith, S. R., and D. M. Kirking. 1999. Access and use of medications in HIV disease. Health Services Research34: 123-144.
39.
Soumerai, S. B., J. Avorn, D. Ross-Degnan, and S. Gortmaker. 1987. Payment restrictions for prescription drugs under Medicaid. New England Journal of Medicine317: 550-556.
40.
StataCorp. 2005. Stata statistical software: Release 9. College Stations, TX: StataCorp LP.
41.
World Health Organization (WHO). 2001. WHO medicines strategy: Revised procedure for updating WHO’s Model List of Essential Drugs. Report by the Secretariat. Retrieved September 5, 2006, from http://www.who.int/gb/ebwha/pdf_files/EB109/eeb1098.pdf%23search=%2522those%2520that%2520satisfy%2520the%2520health%2520care%2520needs%2520of%2520the%2520majority%2520of%2520the%2520population%253B%2522.
42.
United States Census Bureau. 2004. U.S. interim projections by age, sex, race, and Hispanic origin. Retrieved February 14, 2005, from http://www.census.gov/ipc/www/usinterimproj/.
43.
Zito, J. M., D. J. Safer, I. H. Zuckerman, J. F. Gardner, and K. Soeken. 2005. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatric Services56: 157-163.
